ENTITY
SMARTSCORE: 3.6/5
3SBio Inc

3SBio Inc (1530 HK)

123
Analysis
Health CareChina
3SBio, Inc. is a biotechnology company located in China. The Company focuses on mammalian cell-based biopharmaceuticals in the biotechnology industry. 3SBio also develops, manufactures and markets biopharmaceutical products globally.
more
20 Jul 2019 03:52

Hong Kong Short Reporting - Insights from 12 July Data

We analyse the latest SFC data released last evening on short position reporting in Hong Kong for the week ended 12 July.Total short notional in...

Logo
500 Views
Share
19 Jul 2019 03:28

SinoMab (中国抗体): Pipeline Concentrated on Autoimmune Therapy

SinoMab, the first Hong Kong-headquartered biotech company coming to list on the SEHK, plans to raise USD100 to 200 million.  In this insight, we...

Logo
763 Views
Share
02 Jun 2019 20:21

Hansoh Pharma IPO: Valuation Reasonable for the Trade-Offs

Hansoh Pharmaceutical (3692 HK) claims to be one of the few R&D driven Chinese pharmaceutical companies. It announced its IPO price range of...

Logo
793 Views
Share
23 May 2019 01:44

Hansoh Pharma (翰森制药) IPO: Thoughts on Valuation

Hansoh Pharma has started pre-marketing its IPO to raise USD 1bn in its IPO. In our previous insights, we covered the company's major products and...

Logo
855 Views
Share
bearishMabPharm
17 May 2019 07:58

MabPharm (迈博医药) IPO: Fairly Valued and Lacks Biotech Investors

MabPharm, a biotech company backed by CDH Investment, launched book building today. In our previous insights, we have discussed the company's...

Logo
674 Views
Share
x